All Outputs (2)

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial (2016)
Journal Article
Robertson, J. F., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., …Ellis, M. J. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet, 388(10063), 2997-3005. https://doi.org/10.1016/S0140-6736%2816%2932389-3

Background Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic breast cancer. We investigated whether the selective oestrogen receptor degrader fulvestrant could improve progression-free surviva... Read More about Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer (2016)
Journal Article
Hunt, K. K., Karakas, C., Ha, M. J., Biernacka, A., Yi, M., Sahin, A., …Keyomarsi, K. (2017). Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clinical Cancer Research, 23(12), 2991-3002. https://doi.org/10.1158/1078-0432.ccr-16-2217

Background: Low-molecular-weight-cyclin E (LMW-E) detected by Western blot, predicts for reduced breast cancer survival, however, it is impractical for clinical use. LMW-E lacks a nuclear localization signal which leads to accumulation in the cytopla... Read More about Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.